#52026XC03348EU Marketing Authorisation Decisions for Medicinal Products, January-April 2026
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This notice records EU decisions on marketing authorisations for several medicinal products between 1 January and 30 April 2026. It confirms one new authorisation for Dazparda, an insulin aspart injection, and four changes to existing authorisations for Nexavar, Sialanar, LOQTORZI, and Osenvelt. The practical effect is mainly informational for pharmaceutical companies, healthcare regulators, market access teams, and compliance staff. Businesses involved with these medicines should check the European Medicines Agency records for the full assessment reports and details of each decision.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- A new EU marketing authorisation was issued for Dazparda, an insulin aspart solution for injection.
- Existing EU marketing authorisations were modified for Nexavar, Sialanar, LOQTORZI, and Osenvelt.
- Public assessment reports and decision details are available through the European Medicines Agency.